MEDICINOVA INC Form 8-K June 15, 2006

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2006

MEDICINOVA, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

000-51133 (Commission File Number) 33-0927979 (IRS Employer

of incorporation)

4350 La Jolla Village Drive, Suite 950

Identification No.)

San Diego, CA 92122

(Address of principal executive offices) (Zip Code)

Registrant s telephone number, including area code: (858) 373-1500

Not Applicable

(Former name or former address, if changed since last report)

Edgar Filing: MEDICINOVA INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1

Edgar Filing: MEDICINOVA INC - Form 8-K

Item 8.01 Other Events.

On June 13, 2006, MediciNova, Inc. (the Company) announced the initiation of a clinical development program to evaluate MN-221 for the treatment of *status asthmaticus*.

Attached as Exhibit 99.1 hereto and incorporated herein by reference in its entirety is the press release issued by the Company on June 13, 2006.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

Exhibit Description

99.1 Press Release issued June 13, 2006.

Edgar Filing: MEDICINOVA INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 14, 2006.

MEDICINOVA, INC.

By: /s/ Shintaro Asako Shintaro Asako Vice President, Accounting and

Administration

3

EXHIBIT INDEX

Exhibit No.

Description Press Release issued June 13, 2006. 99.1

4